What is Decently?
Decently operates as a specialized medtech platform provider, focusing on the critical intersection of neurology and digital health. Based in Manchester, England, the company develops sophisticated tools designed to monitor and manage brain trauma, addressing a significant gap in clinical data collection and patient outcomes. By integrating advanced analytics with clinical workflows, Decently provides healthcare providers with actionable insights, effectively bridging the divide between complex neurological data and bedside decision-making. Their market position is defined by a commitment to evidence-based medicine and the scalable deployment of diagnostic software in high-acuity clinical environments.
How much funding has Decently raised?
Decently has raised a total of $613K across 1 funding round:
Other Financing Round
$613K
Other Financing Round (2023): $613K with participation from Praetura Ventures, Bruntwood, and SFC Capital
Key Investors in Decently
Praetura Ventures
A venture firm dedicated to supporting entrepreneurs in Northern England and beyond, providing both capital and operational expertise to foster long-term business growth.
Bruntwood
A Manchester-based family-owned property company that provides essential infrastructure and office space to support the growth of regional businesses.
SFC Capital
A highly active UK-based seed investor specializing in SEIS and EIS-qualifying businesses across diverse sectors including biotech and fintech.
What's next for Decently?
With the successful closure of this major enterprise-level funding round, Decently is poised to transition into a phase of rapid commercial scaling and product expansion. The strategic allocation of these funds will likely prioritize the enhancement of their core diagnostic platform, the expansion of clinical trial partnerships, and the strengthening of their regulatory compliance framework to facilitate broader market entry. As the company continues to refine its technological stack, the focus will remain on achieving long-term sustainability and establishing itself as a standard-bearer for brain trauma management solutions. Investors are closely monitoring the firm's ability to translate this capital into measurable clinical impact and expanded market share across the United Kingdom and beyond.
See full Decently company page
